Related Experiment Video
Updated: Jul 12, 2026
The Influence of Liver Resection on Intrahepatic Tumor Growth
Published on: April 9, 2016
Biological treatment for liver tumor and new potential biomarkers
Maurizio Chiriva-Internati1, Fabio Grizzi, Mitchell S Wachtel
1Department of Microbiology and Immunology, Texas Tech University Health Science Center, Lubbock, TX 79430, USA. maurizio.chiriva@ttuhsc.edu
Abstract:
The search for effective and efficacious therapy for liver tumor was started many years ago and is still ongoing. Despite all of the surgical advances, much work needs to be done to improve understanding of the biology of the tumor and its treatment. The rules of hepatic surgery are changing because of two recent major trends: (1) technical simplification, and (2) the endeavor to treat an increasing number of patients. T lymphocytes are potent cellular effectors of the immune system and possess a memory that responds to rechallenge by the same antigen. Being more specific and less toxic than chemotherapy, tumor infusion could be an ideal adjuvant therapy for patients with primary and secondary liver malignancies. Moreover, tumor cell vaccines have demonstrated efficacy in terms of minimal residual disease and are being investigated, but the requirement for an adequate supple of autologos tumor may limit the general applicability of these approaches. Various studies have demonstrated the aberrant expression of germ-cell proteins called cancer-testis (CT) antigens in liver neoplastic cells. Their selective normal-tissue expression makes them ideal antigens for immune targeting of malignant disease. Specific expression of CT antigens also suggests their application as tumor markers to detect circulating hepatocellular carcinoma (HCC) cells, as an adjuvant diagnostic tool, and as indicators for recurrence and prognosis. Biological therapy is now generating more clinical trials. More studies need to be performed and further experiments need to be done, although currently this seems a valid pathway for the treatment of liver cancer. Cytoreduction treatment of liver tumor and the vaccine might be the future of the treatment of primary and secondary liver tumor.
Insights
Biological therapies, including T lymphocyte infusions and cancer-testis antigen vaccines, show promise for liver cancer treatment. These approaches offer targeted, less toxic options compared to chemotherapy, potentially improving outcomes for primary and secondary liver malignancies.
Area of Science:
- Oncology
- Immunology
- Hepatology
Background:
- Liver tumor treatment research is ongoing, with evolving surgical techniques and a growing need for improved therapies.
- T lymphocytes are key immune cells with memory, offering specific and less toxic alternatives to chemotherapy.
- Cancer-testis (CT) antigens are aberrantly expressed in liver cancer cells, making them potential targets for immunotherapy and diagnostic markers.
Purpose of the Study:
- To explore the potential of biological therapies, including T lymphocyte infusions and CT antigen-based vaccines, for treating liver malignancies.
- To evaluate the efficacy and applicability of these novel immunotherapeutic strategies in liver cancer.
- To discuss the role of CT antigens as potential biomarkers for hepatocellular carcinoma (HCC).
Main Methods:
- Review of current research on T lymphocyte-based therapies and tumor cell vaccines for liver cancer.
- Analysis of studies investigating cancer-testis (CT) antigens in liver neoplastic cells.
- Exploration of the diagnostic and prognostic potential of CT antigens in hepatocellular carcinoma (HCC).
Main Results:
- Tumor infusion with T lymphocytes is a potential adjuvant therapy for liver malignancies due to its specificity and lower toxicity.
- Cancer-testis (CT) antigens are selectively expressed in liver tumors, making them suitable targets for immune-based therapies.
- CT antigens show potential as tumor markers for detecting circulating HCC cells and indicating prognosis.
Conclusions:
- Biological therapies, particularly T lymphocyte infusions and CT antigen vaccines, represent a promising future direction for liver cancer treatment.
- Further research and clinical trials are necessary to fully establish the efficacy and widespread applicability of these immunotherapeutic approaches.
- CT antigens hold significant potential for both targeted liver cancer therapy and as diagnostic/prognostic biomarkers for HCC.
